[go: up one dir, main page]

CA3125383A1 - Analogues peptidiques de conotoxine et leurs utilisations pour le traitement de la douleur et d'affections inflammatoires - Google Patents

Analogues peptidiques de conotoxine et leurs utilisations pour le traitement de la douleur et d'affections inflammatoires Download PDF

Info

Publication number
CA3125383A1
CA3125383A1 CA3125383A CA3125383A CA3125383A1 CA 3125383 A1 CA3125383 A1 CA 3125383A1 CA 3125383 A CA3125383 A CA 3125383A CA 3125383 A CA3125383 A CA 3125383A CA 3125383 A1 CA3125383 A1 CA 3125383A1
Authority
CA
Canada
Prior art keywords
peptide analog
conotoxin peptide
pharmaceutically acceptable
acceptable salt
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3125383A
Other languages
English (en)
Inventor
Jose Mercado
Eric J. Tarcha
Jeffrey J. Posakony
Shawn Iadonato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Chronic Pain LLC
Original Assignee
Kineta Chronic Pain LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Chronic Pain LLC filed Critical Kineta Chronic Pain LLC
Publication of CA3125383A1 publication Critical patent/CA3125383A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des analogues peptidiques d'alpha-conotoxine, notamment des analogues peptidiques d'alpha-conotoxine qui sont liés de manière covalente au polyéthylène glycol (PEG), et des compositions pharmaceutiques de tels analogues peptidiques d'alpha-conotoxine. L'invention concerne également des méthodes de traitement ou de prévention d'une affection favorable au traitement ou à la prévention par inhibition d'un récepteur nicotinique de l'acétylcholine (nAChR) contenant a9 (par exemple, le sous-type a9a10 du nAChR) chez un sujet.
CA3125383A 2019-01-04 2019-01-04 Analogues peptidiques de conotoxine et leurs utilisations pour le traitement de la douleur et d'affections inflammatoires Pending CA3125383A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/012307 WO2020142102A1 (fr) 2019-01-04 2019-01-04 Analogues peptidiques de conotoxine et leurs utilisations pour le traitement de la douleur et d'affections inflammatoires

Publications (1)

Publication Number Publication Date
CA3125383A1 true CA3125383A1 (fr) 2020-07-09

Family

ID=65244618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3125383A Pending CA3125383A1 (fr) 2019-01-04 2019-01-04 Analogues peptidiques de conotoxine et leurs utilisations pour le traitement de la douleur et d'affections inflammatoires

Country Status (16)

Country Link
EP (1) EP3906253A1 (fr)
JP (1) JP2022522935A (fr)
KR (1) KR20210116505A (fr)
CN (1) CN113966339A (fr)
AU (1) AU2019418319B2 (fr)
BR (1) BR112021013302A2 (fr)
CA (1) CA3125383A1 (fr)
CL (1) CL2021001775A1 (fr)
CO (1) CO2021008845A2 (fr)
CR (1) CR20210363A (fr)
IL (1) IL284574A (fr)
MX (1) MX2021008070A (fr)
PE (1) PE20211734A1 (fr)
PH (1) PH12021551624A1 (fr)
SG (1) SG11202106847SA (fr)
WO (1) WO2020142102A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230033485A (ko) 2021-09-01 2023-03-08 삼성전자주식회사 저장 장치 및 그의 동작 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717775B2 (en) * 2006-07-18 2017-08-01 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US9284358B2 (en) * 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
US20090326192A1 (en) * 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
CN102875654B (zh) * 2012-09-25 2014-07-09 中国人民解放军军事医学科学院生物工程研究所 芋螺毒素多肽Eb1.6的制备方法
EP2970389B1 (fr) * 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Compositions pharmaceutiques
CN107249616A (zh) * 2014-11-07 2017-10-13 奇尼塔慢性疼痛有限责任公司 芋螺毒素(conotoxin)肽的修饰和用途

Also Published As

Publication number Publication date
PH12021551624A1 (en) 2022-05-23
PE20211734A1 (es) 2021-09-06
BR112021013302A2 (pt) 2021-09-14
AU2019418319B2 (en) 2025-08-21
SG11202106847SA (en) 2021-07-29
CO2021008845A2 (es) 2021-10-29
KR20210116505A (ko) 2021-09-27
JP2022522935A (ja) 2022-04-21
CN113966339A (zh) 2022-01-21
WO2020142102A9 (fr) 2020-11-19
IL284574A (en) 2021-08-31
EP3906253A1 (fr) 2021-11-10
CL2021001775A1 (es) 2022-05-27
MX2021008070A (es) 2021-10-13
AU2019418319A1 (en) 2021-07-22
WO2020142102A1 (fr) 2020-07-09
CR20210363A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
US10894808B2 (en) Polypeptide ligands specific for plasma kallikrein
CA2862038C (fr) Macrocycles peptidomimetiques
EP3201217A1 (fr) Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine
KR20220035199A (ko) 인크레틴 유사체의 제조 방법
WO2018128828A1 (fr) Nouveaux mimétiques d'hepcidine et leurs utilisations
US5204328A (en) Peptides having atrial natriuretic factor activity
AU2015323769A1 (en) Stabilized adrenomedullin derivatives and use thereof
EP2755690B1 (fr) Conjugués du kisspeptide avec un pentasaccharide
US11975040B2 (en) Plexin binding regulator
CA3229962A1 (fr) Conjugue anticorps-peptide se liant au recepteur de la transferrine humaine
CA3125383A1 (fr) Analogues peptidiques de conotoxine et leurs utilisations pour le traitement de la douleur et d'affections inflammatoires
US11612661B2 (en) Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
JP2023156531A (ja) Ｖｅｇｆ結合ペプチド
CA3143584A1 (fr) Analogues d'adrenomedulline pour stabilisation a long terme et leur utilisation
WO2024029242A1 (fr) Nouveau peptide de liaison à lrp1
TW202026305A (zh) 芋螺毒素(conotoxin)肽類似物及用於疼痛及發炎病症之治療的用途
WO2025226506A1 (fr) Composés mono- et doubles agonistes de glp1r et gipr humains pour l'obésité et t2dm
HK40013212A (en) Compstatin peptides with improved pharmacokinetic properties
HK1227702A1 (en) Novel polypeptides
HK1227702B (en) Novel polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231221

EEER Examination request

Effective date: 20231221